TP53 mutation-correlated genes predict the risk of tumor relapse and identify MPS1 as a potential therapeutic kinase in TP53-mutated breast cancers

Molecular Oncology

Volumn 8, Issue 3, 2014, Pages 508-519

  Gyorffy, Balázs ^a,b   Bottai, Giulia ^c   Lehmann Che, Jacqueline ^d   Kéri, György ^e,f   Orfi, László ^e,f   Iwamoto, Takayuki ^g   Desmedt, Christine ^h   Bianchini, Giampaolo ⁱ   Turner, Nicholas C ^j   de Thè, Hugues ^d   André, Fabrice ^k   Sotiriou, Christos ^k   Hortobagyi, Gabriel N ^l   Di Leo, Angelo ^c   Pusztai, Lajos ^m   Santarpia, Libero ^c,n  

^a INSTITUTE OF EXPERIMENTAL MEDICINE   (Hungary)

^b SEMMELWEIS UNIVERSITY   (Hungary)

^c ISTITUTO TOSCANO TUMORI   (Italy)

^d Institut Universitaire d'Hématologie   (France)

^e SEMMELWEIS UNIVERSITY   (Hungary)

^f Vichem Chemie Research Ltd   (Hungary)

^g OKAYAMA UNIVERSITY HOSPITAL   (Japan)

^h JULES BORDET INSTITUTE   (Belgium)

ⁱ SAN RAFFAELE HOSPITAL   (Italy)

^j INSTITUTE OF CANCER RESEARCH   (United Kingdom)

^k INSERM   (France)

^l UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

^m YALE CANCER CENTER   (United States)

ⁿ HUMANITAS CLINICAL AND RESEARCH CENTER   (Italy)

more..

Author keywords

Breast cancer subtypes; Chemotherapy; MPS1 protein kinase; SP600125; TP53 mutation status; Tumor relapse

Indexed keywords

ANTHRA[1,9 CD]PYRAZOL 6(2H) ONE; ANTINEOPLASTIC AGENT; ESTROGEN RECEPTOR; MPS1 PROTEIN; PROTEIN; PROTEIN P53; SMALL INTERFERING RNA; UNCLASSIFIED DRUG; ANTHRA(1,9-CD)PYRAZOL-6(2H)-ONE; ANTHRACENE DERIVATIVE; CELL CYCLE PROTEIN; PROTEIN SERINE THREONINE KINASE; PROTEIN TYROSINE KINASE; TTK PROTEIN, HUMAN;

ADJUVANT THERAPY; ARTICLE; BREAST CANCER; CANCER ADJUVANT THERAPY; CANCER CELL; CANCER COMBINATION CHEMOTHERAPY; CANCER PROGNOSIS; CANCER RISK; CELL DEATH; CELL VIABILITY; CHEMOSENSITIZATION; GENE EXPRESSION PROFILING; HUMAN; HUMAN CELL; M PHASE CELL CYCLE CHECKPOINT; PREDICTION; PRIORITY JOURNAL; RECEIVER OPERATING CHARACTERISTIC; RELAPSE; ANTAGONISTS AND INHIBITORS; BREAST; BREAST NEOPLASMS; CELL SURVIVAL; DRUG EFFECTS; FEMALE; GENETICS; METABOLISM; MUTATION; NEOPLASM RECURRENCE, LOCAL; PATHOLOGY; PROGNOSIS; SURVIVAL; TUMOR CELL LINE; TUMOR SUPPRESSOR GENE;

ANTHRACENES; BREAST; BREAST NEOPLASMS; CELL CYCLE PROTEINS; CELL LINE, TUMOR; CELL SURVIVAL; FEMALE; GENES, P53; HUMANS; MUTATION; NEOPLASM RECURRENCE, LOCAL; PROGNOSIS; PROTEIN-SERINE-THREONINE KINASES; PROTEIN-TYROSINE KINASES; SURVIVAL ANALYSIS; TUMOR SUPPRESSOR PROTEIN P53;

EID: 84899488362     PISSN: 15747891     EISSN: 18780261     Source Type: Journal    
DOI: 10.1016/j.molonc.2013.12.018     Document Type: Article

References (56)

1. Allred D.C., Clark G.M., Elledge R., Fuqua S.A., Brown R.W., Chamness G.C., Osborne C.K., McGuire W.L. Association of p53 protein expression with tumor cell proliferation rate and clinical outcome in node-negative breast cancer. J.Natl. Cancer Inst. 1993, 85:200-206.
2. Bailey S.T., Shin H., Westerling T., Liu X.S., Brown M. Estrogen receptor prevents p53-dependent apoptosis in breast cancer. Proc. Natl. Acad. Sci. U S A 2012, 109:18060-18065.
3. Bertheau P., Turpin E., Rickman D.S., Espié M., de Reyniès A., Feugeas J.P., Plassa L.F., Soliman H., Varna M., de Roquancourt A., Lehmann-Che J., Beuzard Y., Marty M., Misset J.L., Janin A., de Thé H. Exquisite sensitivity of TP53 mutant and basal breast cancers to a dose-dense epirubicin-cyclophosphamide regimen. PLoS. Med. 2007, 4:e90.
4. Bianchini G., Iwamoto T., Qi Y., Coutant C., Shiang C.Y., Wang B., Santarpia L., Valero V., Hortobagyi G.N., Symmans W.F., Gianni L., Pusztai L. Prognostic and therapeutic implications of distinct kinase expression patterns in different subtypes of breast cancer. Cancer Res. 2010, 70:8852-8862.
5. Bonnefoi H., Piccart M., Bogaerts J., Mauriac L., Fumoleau P., Brain E., Petit T., Rouanet P., Jassem J., Blot E., Zaman K., Cufer T., Lortholary A., Lidbrink E., André S., Litière S., Lago L.D., Becette V., Cameron D.A., Bergh J., Iggo R. TP53 status for prediction of sensitivity to taxane versus non-taxane neoadjuvant chemotherapy in breast cancer (EORTC 10994/BIG 1-00): a randomised phase 3 trial. Lancet Oncol. 2011, 12:527-539. EORTC 10994/BIG 1-00 Study Investigators.
6. Brown C.J., Lain S., Verma C.S., Fersht A.R., Lane D.P. Awakening guardian angels: drugging the p53 pathway. Nat. Rev. Cancer 2009, 9:862-873.
7. Cancer Genome Atlas Network Comprehensive molecular portraits of human breast tumors. Nature 2012, 490:61-70.
8. Carter S.L., Eklund A.C., Kohane I.S., Harris L.N., Szallasi Z. A signature of chromosomal instability inferred from gene expression profiles predicts clinical outcome in multiple human cancers. Nat. Genet. 2006, 38:104-1048.
9. Cheok C.F., Verma C.S., Baselga J., Lane D.P. Translating p53 into the clinic. Nat. Rev. Clin. Oncol. 2011, 8:25-37.
10. Ciriello G., Sinha R., Hoadley K.A., Jacobsen A.S., Reva B., Perou C.M., Sander C., Schultz N. The molecular diversity of Luminal A breast tumors. Breast Cancer Res. Treat 2013, 141:409-420.
11. Colombo R., Caldarelli M., Mennecozzi M., Giorgini M.L., Sola F., Cappella P., Perrera C., Depaolini S.R., Rusconi L., Cucchi U., Avanzi N., Bertrand J.A., Bossi R.T., Pesenti E., Galvani A., Isacchi A., Colotta F., Donati D., Moll J. Targeting the mitotic checkpoint for cancer therapy with NMS-P715, an inhibitor of MPS1 kinase. Cancer Res. 2010, 70:10255-10264.
12. Coutant C., Rouzier R., Qi Y., Lehmann-Che J., Bianchini G., Iwamoto T., Hortobagyi G.N., Symmans W.F., Uzan S., Andre F., de Thé H., Pusztai L. Distinct p53 gene signatures are needed to predict prognosis and response to chemotherapy in ER-positive and ER-negative breast cancers. Clin. Cancer Res. 2011, 17:2591-2601.
13. Daniel J., Coulter J., Woo J.H., Wilsbach K., Gabrielson E. High levels of the Mps1 checkpoint protein are protective of aneuploidy in breast cancer cells. Proc. Natl. Acad. Sci. U S A 2011, 108:5384-5389.
14. Desmedt C., Giobbie-Hurder A., Neven P., Paridaens R., Christiaens M.R., Smeets A., Lallemand F., Haibe-Kains B., Viale G., Gelber R.D., Piccart M., Sotiriou C. The gene expression grade Index: a potential predictor of relapse for endocrine-treated breast cancer patients in the BIG 1-98 trial. BMC. Med. Genomics 2009, 2:40.
15. Desmedt C., Di Leo A., de Azambuja E., Larsimont D., Haibe-Kains B., Selleslags J., Delaloge S., Duhem C., Kains J.P., Carly B., Maerevoet M., Vindevoghel A., Rouas G., Lallemand F., Durbecq V., Cardoso F., Salgado R., Rovere R., Bontempi G., Michiels S., Buyse M., Nogaret J.M., Qi Y., Symmans F., Pusztai L., D'Hondt V., Piccart-Gebhart M., Sotiriou C. Multifactorial approach to predicting resistance to anthracyclines. J.Clin. Oncol. 2011, 29:1578-1586.
16. Finetti P., Cervera N., Charafe-Jauffret E., Chabannon C., Charpin C., Chaffanet M., Jacquemier J., Viens P., Birnbaum D., Bertucci F. Sixteen-kinase gene expression identifies luminal breast cancers with poor prognosis. Cancer Res. 2008, 68:767-776.
17. Fredlund E., Staaf J., Rantala J.K., Kallioniemi O., Borg A., Ringnér M. The gene expression landscape of breast cancer is shaped by tumor protein p53 status and epithelial-mesenchymal transition. Breast Cancer Res. 2012, 14:R113.
18. Gyorffy B., Benke Z., Lánczky A., Balázs B., Szállási Z., Timár J., Schäfer R. Recurrence online: an online analysis tool to determine breast cancer recurrence and hormone receptor status using microarray data. Breast Cancer Res. Treat. 2012, 132:1025-1034.
19. Gyorffy B., Lanczky A., Eklund A.C., Denkert C., Budczies J., Li Q., Szallasi Z. An online survival analysis tool to rapidly assess the effect of 22,277 genes on breast cancer prognosis using microarray data of 1,809 patients. Breast Cancer Res. Treat. 2010, 123:725-731.
20. Gyorffy B., Molnar B., Lage H., Szallasi Z., Eklund A.C. Evaluation of microarray preprocessing algorithms based on concordance with RT-PCR in clinical samples. PLoS. One 2009, 4:e5645.
21. Gyorffy B., Schafer R. Meta-analysis of gene expression profiles related to relapse-free survival in 1,079 breast cancer patients. Breast Cancer Res. Treat. 2009, 118:433-441.
22. Ha G.H., Breuer E.K. Mitotic kinases and p53 signaling. Biochem. Res. Int. 2012, 2012:195903.
23. Hatzis C., Pusztai L., Valero V., Booser D.J., Esserman L., Lluch A., Vidaurre T., Holmes F., Souchon E., Wang H., Martin M., Cotrina J., Gomez H., Hubbard R., Chacón J.I., Ferrer-Lozano J., Dyer R., Buxton M., Gong Y., Wu Y., Ibrahim N., Andreopoulou E., Ueno N.T., Hunt K., Yang W., Nazario A., DeMichele A., O'Shaughnessy J., Hortobagyi G.N., Symmans W.F. A genomic predictor of response and survival following taxane-anthracycline chemotherapy for invasive breast cancer. JAMA 2011, 305:1873-1881.
24. Huang D.W., Sherman B.T., Lempicki R.A. Systematic and integrative analysis of large gene lists using DAVID bioinformatics resources. Nat. Protoc. 2009, 4:44-57.
25. Huang D.W., Sherman B.T., Lempicki R.A. Bioinformatics enrichment tools: paths toward the comprehensive functional analysis of large gene lists. Nucleic Acids Res. 2009, 37:1-13.
26. Huang Y.F., Chang M.D., Shieh S.Y. TTK/hMps1 mediates the p53-dependent postmitotic checkpoint by phosphorylating p53 at Thr18. Mol. Cell. Biol. 2009, 29:2935-2944.
27. Iwamoto T., Bianchini G., Booser D., Qi Y., Coutant C., Shiang C.Y., Santarpia L., Matsuoka J., Hortobagyi G.N., Symmans W.F., Holmes F.A., O'Shaughnessy J., Hellerstedt B., Pippen J., Andre F., Simon R., Pusztai L. Gene pathways associated with prognosis and chemotherapy sensitivity in molecular subtypes of breast cancer. J.Natl. Cancer Inst. 2011, 103:264-272.
28. Janssen A., Kops G.J., Medema R.H. Elevating the frequency of chromosome mis-segregation as a strategy to kill tumor cells. Proc. Natl. Acad. Sci. U S A 2009, 106:19108-19113.
29. Jemaà M., Galluzzi L., Kepp O., Senovilla L., Brands M., Boemer U., Koppitz M., Lienau P., Prechtl S., Schulze V., Siemeister G., Wengner A.M., Mumberg D., Ziegelbauer K., Abrieu A., Castedo M., Vitale I., Kroemer G. Characterization of novel MPS1 inhibitors with preclinical anticancer activity. Cell. Death Differ. 2013.
30. Jemaà M., Vitale I., Kepp O., Berardinelli F., Galluzzi L., Senovilla L., Mariño G., Malik S.A., Rello-Varona S., Lissa D., Antoccia A., Tailler M., Schlemmer F., Harper F., Pierron G., Castedo M., Kroemer G. Selective killing of p53-deficient cancer cells by SP600125. EMBO. Mol. Med. 2012, 4:500-514.
31. Jones M.H., Huneycutt B.J., Pearson C.G., Zhang C., Morgan G., Shokat K., Bloom K., Winey M. Chemical genetics reveals a role for Mps1 kinase in kinetochore attachment during mitosis. Curr. Biol. 2005, 15:160-165.
32. Kanehisa M., Goto S. KEGG: Kyoto encyclopedia of genes and genomes. Nucleic Acids Res. 2000, 28:27-30.
33. Karn T., Pusztai L., Holtrich U., Iwamoto T., Shiang C.Y., Schmidt M., Müller V., Solbach C., Gaetje R., Hanker L., Ahr A., Liedtke C., Ruckhäberle E., Kaufmann M., Rody A. Homogeneous datasets of triple negative breast cancers enable the identification of novel prognostic and predictive signatures. PLoS. One 2011, 6:e28403.
34. Kim M., Wiemer D.F. EDC-mediated condensations of 1-chloro-5-hydrazino-9,10-anthracenedione, 1-hydrazino-9,10-anthracenedione, and the corresponding anthrapyrazoles. Tetrahedron Lett. 2004, 45:4977-4980.
35. Leng M., Chan D.W., Luo H., Zhu C., Qin J., Wang Y. MPS1-dependent mitotic BLM phosphorylation is important for chromosome stability. Proc. Natl. Acad. Sci. U S A 2006, 103:11485-11490.
36. Li Q., Birkbak N.J., Gyorffy B., Szallasi Z., Eklund A.C. Jetset: selecting the optimal microarray probe set to represent a gene. BMC. Bioinfo. 2011, 12:474.
37. Liu J., Cheng X., Zhang Y., Li S., Cui H., Zhang L., Shi R., Zhao Z., He C., Wang C., Zhao H., Zhang C., Fisk H.A., Guadagno T.M., Cui Y. Phosphorylation of Mps1 by BRAFV600E prevents Mps1 degradation and contributes to chromosome instability in melanoma. Oncogene 2013, 32:713-723.
38. Maire V., Baldeyron C., Richardson M., Tesson B., Vincent-Salomon A., Gravier E., Marty-Prouvost B., De Koning L., Rigaill G., Dumont A., Gentien D., Barillot E., Roman-Roman S., Depil S., Cruzalegui F., Pierré A., Tucker G.C., Dubois T. TTK/hMPS1 is an attractive therapeutic target for triple-negative breast cancer. PLoS. One 2013, 8:e63712.
39. Miller L.D., Smeds J., George J., Vega V.B., Vergara L., Ploner A., Pawitan Y., Hall P., Klaar S., Liu E.T., Bergh J. An expression signature for p53 status in human breast cancer predicts mutation status, transcriptional effects, and patient survival. Proc. Natl. Acad. Sci. U S A 2005, 102:13550-13555.
40. Moher D., Liberati A., Tetzlaff J., Altman D.G. Preferred reporting items for systematic reviews and meta-analyses: the PRISMA Statement. Open. Med. 2009, 3:e123-130.
41. Murray S., Briasoulis E., Linardou H., Bafaloukos D., Papadimitriou C. Taxane resistance in breast cancer: mechanisms, predictive biomarkers and circumvention strategies. Cancer Treat. Rev. 2012, 38:890-903.
42. Neve R.M., Chin K., Fridlyand J., Yeh J., Baehner F.L., Fevr T., Clark L., Bayani N., Coppe J.P., Tong F., Speed T., Spellman P.T., DeVries S., Lapuk A., Wang N.J., Kuo W.L., Stilwell J.L., Pinkel D., Albertson D.G., Waldman F.M., McCormick F., Dickson R.B., Johnson M.D., Lippman M., Ethier S., Gazdar A., Gray J.W. A collection of breast cancer cell lines for the study of functionally distinct cancer subtypes. Cancer Cell. 2006, 10:515-527.
43. Olivier M., Langerød A., Carrieri P., Bergh J., Klaar S., Eyfjord J., Theillet C., Rodriguez C., Lidereau R., Bièche I., Varley J., Bignon Y., Uhrhammer N., Winqvist R., Jukkola-Vuorinen A., Niederacher D., Kato S., Ishioka C., Hainaut P., Børresen-Dale A.L. The clinical value of somatic TP53 gene mutations in 1,794 patients with breast cancer. Clin. Cancer Res. 2006, 12:1157-1167.
44. Reme T., Hose D., Theillet C., Klein B. Modeling risk stratification in human cancer. Bioinformatics 2013, 29:1149-1157.
45. Santarpia L., Iwamoto T., Di Leo A., Hayashi N., Bottai G., Stampfer M., Andre F., Turner N.C., Symmans W.F., Hortobagyi G.N., Pusztai L., Bianchini G. DNA repair gene patterns as prognostic and predictive factors in molecular breast cancer subtypes. Oncologist 2013, 18:1063-1073.
46. Santarpia L., Qi Y., Stemke-Hale K., Wang B., Young E.J., Booser D.J., Holmes F.A., O'Shaughnessy J., Hellerstedt B., Pippen J., Vidaurre T., Gomez H., Valero V., Hortobagyi G.N., Symmans W.F., Bottai G., Di Leo A., Gonzalez-Angulo A.M., Pusztai L. Mutation profiling identifies numerous rare drug targets and distinct mutation patterns in different clinical subtypes of breast cancers. Breast Cancer Res. Treat. 2012, 13:333-343.
47. Sotiriou C., Pusztai L. Gene-expression signatures in breast cancer. N.Engl. J. Med. 2009, 360:790-800.
48. Sotiriou C., Wirapati P., Loi S., Harris A., Fox S., Smeds J., Nordgren H., Farmer P., Praz V., Haibe-Kains B., Desmedt C., Larsimont D., Cardoso F., Peterse H., Nuyten D., Buyse M., Van de Vijver M.J., Bergh J., Piccart M., Delorenzi M. Gene expression profiling in breast cancer: understanding the molecular basis of histologic grade to improve prognosis. J.Natl. Cancer Inst. 2006, 98:262-272.
49. Tannous B.A., Kerami M., Van der Stoop P.M., Kwiatkowski N., Wang J., Zhou W., Kessler A.F., Lewandrowski G., Hiddingh L., Sol N., Lagerweij T., Wedekind L., Niers J.M., Barazas M., Nilsson R.J., Geerts D., De Witt Hamer P.C., Hagemann C., Vandertop W.P., Van Tellingen O., Noske D.P., Gray N.S., Würdinger T. Effects of the selective MPS1 inhibitor MPS1-IN-3 on glioblastoma sensitivity to antimitotic drugs. J.Natl. Cancer Inst. 2013, 105:1322-1331.
50. Troester M.A., Herschkowitz J.I., Oh D.S., He X., Hoadley K.A., Barbier C.S., Perou C.M. Gene expression patterns associated with p53 status in breast cancer. BMC. Cancer 2006, 6:276.
51. Turner N., Moretti E., Siclari O., Migliaccio I., Santarpia L., D'Incalci M., Piccolo S., Veronesi A., Zambelli A., Del Sal G., Di Leo A. Targeting triple negative breast cancer: is p53 the answer?. Cancer Treat. Rev. 2013, 39:541-550.
52. Walerych D., Napoli M., Collavin L., Del Sal G. The rebel angel: mutant p53 as the driving oncogene in breast cancer. Carcinogenesis 2012, 33:2007-2017.
53. Weaver B.A., Cleveland D.W. Decoding the links between mitosis, cancer, and chemotherapy: the mitotic checkpoint, adaptation, and cell death. Cancer Cell. 2005, 8:7-12.
54. Wei J.H., Chou Y.F., Ou Y.H., Yeh Y.H., Tyan S.W., Sun T.P., Shen C.Y., Shieh S.Y. TTK/hMps1 participates in the regulation of DNA damage checkpoint response by phosphorylating CHK2 on threonine 68. J.Biol. Chem. 2005, 280:7748-7757.
55. Weiss E., Winey M. The Saccharomyces cerevisiae spindle pole body duplication gene MPS1 is part of a mitotic checkpoint. J.Cell. Biol. 1996, 132:111-123.
56. Yerushalmi R., Woods R., Ravdin P.M., Hayes M.M., Gelmon K.A. Ki67 in breast cancer: prognostic and predictive potential. Lancet Oncol. 2010, 11:174-183.